# Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects

> **NCT03235076** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** BAY1101042

## Key facts

- **NCT ID:** NCT03235076
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2018-11-07
- **Final completion:** 2019-03-13
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235076, "Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03235076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*